Phase II Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases (BEAT-MBM)
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms BEAT-MBM
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Feb 2018 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 15 Jun 2017 Status changed from not yet recruiting to recruiting.